New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
12:56 EDTABBV, PRGOPerrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0%
Perrigo Company (PRGO) announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration for its previously approved New Drug Application for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to AndroGel 1% (ABBV) and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling. Other companies that have submitted NDAs referencing AndroGel 1.0% have failed to achieve the AB rating.
News For PRGO;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:30 EDTPRGODeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:03 EDTABBVLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:17 EDTABBVAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
06:25 EDTPRGOPerrigo downgraded to Sector Perform from Outperform at RBC Capital
March 20, 2015
07:41 EDTABBVAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
08:47 EDTABBVAbbVie and C2N sign worlwide license agreement for Alzheimer's Disease therapy
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
07:56 EDTABBVAbbVie plans $30M expansion at plant in Puerto Rico, AP reports
AbbVie is planning to expand one of its facilities in Barceloneta, Puerto Rico, The Associated Press reports. The $30M expansion is slated for a plant that manufactures products related to immunology, virology and metabolic disorders. Reference Link
March 17, 2015
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
15:04 EDTABBVPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use